Dianthus Therapeutics (87E) Price & Analysis

0 Followers

87E Stock Chart & Stats

€90.00

-€2.00(-2.16%)

At close: Jul 28 4:00 PM EDT

€90.00

-€2.00(-2.16%)

Day’s Range― - ―

52-Week Range€28.40 - €99.50

Previous CloseN/A

Volume67.00

Average Volume (3M)3.00

Market Cap

€4.39B

Enterprise Value€4.58B

Total Cash (Recent Filing)€886.81M

Total Debt (Recent Filing)€1.29M

Price to Earnings (P/E)―

Beta0.17

Next Earnings

Nov 05, 2026

EPS Estimate

-0.83

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding55,934,380

10 Day Avg. Volume1

30 Day Avg. Volume3

Financial Highlights & Ratios

PEG Ratio-0.15

Price to Book (P/B)3.16

Price to Sales (P/S)764.98

P/FCF Ratio-12.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€126.84

Price Target Upside40.94% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-3.37

Revenue Forecast (FY)€1.67M

Bulls Say, Bears Say

Bulls Say

Low Leverage And Expanding Capital BaseMinimal debt reduces financial risk and preserves flexibility while Dianthus funds clinical development. The expansion in equity and total assets provides a larger capital base for continued research and operations, supporting runway even though the company has not yet reached profitability.

Clinical Program MomentumThe interim Phase 3 response signal supports the lead program’s development momentum and could strengthen the company’s position in severe autoimmune disease. If sustained through later analysis and regulatory progress, clinical validation may improve future commercialization potential and financing access.

High Gross EconomicsVery high gross margins indicate favorable underlying economics on the revenue currently recognized. Although revenue remains limited, preserving strong gross profitability could support future operating leverage if clinical success enables broader commercialization and meaningfully greater scale.

Bears Say

Escalating Cash BurnOperating cash outflows have become materially more negative over time, making cash consumption the company’s central financial weakness. Continued clinical investment will likely require substantial funding, and rising burn can reduce flexibility if development timelines extend or financing conditions become less favorable.

Persistent Operating LossesDianthus remains in a heavy investment phase without operating profitability, so its capital base is not yet generating returns. Persistent and widening losses increase the amount of external capital needed to advance programs and make future earnings dependent on successful clinical and commercial execution.

No Recurring Commercial RevenueWithout marketed products, Dianthus lacks a recurring revenue stream to fund research, development, and corporate costs. Operations therefore depend primarily on financing activities, leaving the business exposed to dilution and the need to secure additional capital before commercial revenues emerge.

Dianthus Therapeutics News

Dianthus files automatic mixed securities shelf

16:03 EDT Dianthus (DNTH) files automatic mixed securities shelf Published first on TheFly – the ultimate source for...

17d ago

DNTH

Dianthus participates in a conference call with JPMorgan

Biotech Analysts hold a conference call with management on September 18 at 11 am hosted by JPMorgan.Webcast Link...

17d ago

DNTH

Dianthus initiated with an Overweight at JPMorgan

JPMorgan analyst Brian Cheng initiated coverage of Dianthus (DNTH) with an Overweight rating and $135 price target Dianthus...

24d ago

DNTH

Dianthus Reaffirmed at Buy as Claseprubart Data Strengthen Neuromuscular Outlook; Price Target Maintained at $125

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Dianthus Therapeutics today and set a price target...

6d ago

DNTH

Analyst Reiterates Buy on Dianthus as Claseprubart Data Momentum and New Pipeline Assets Strengthen Risk-Reward Profile

William Blair analyst Myles Minter has reiterated their bullish stance on DNTH stock, giving a Buy rating on...

17d ago

DNTH

UiPath downgraded, Shell upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

LEN

ORA

Dianthus initiated with a Buy at Citi

Citi analyst Samantha Semenkow initiated coverage of Dianthus (DNTH) with a Buy rating and $156 price target The...

1M ago

DNTH

Dianthus price target raised to $128 from $110 at Truist

Truist raised the firm’s price target on Dianthus (DNTH) to $128 from $110 and keeps a Buy rating...

2M ago

DNTH

Dianthus price target raised to $158 from $130 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Dianthus (DNTH) to $158 from $130 and keeps a Buy...

2M ago

DNTH

Dianthus price target raised to $122 from $105 at Wedbush

Wedbush raised the firm’s price target on Dianthus (DNTH) to $122 from $105 and keeps an Outperform rating...

2M ago

DNTH

Dianthus Maintained at Buy as Strong Cash Runway and DNTH312 Pipeline Potential Support Unchanged $125 Price Target

Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Dianthus Therapeutics and keeping the price target...

2M ago

DNTH

Dianthus reports Q2 EPS (90c), consensus (91c)

Reports Q2 revenue $761,000, consensus $248,750. “Our strong execution in the first half of 2026 reflects the continued...

2M ago

DNTH

Dianthus Advances Claseprubart Into Phase 3 EMERGE Trial, Raising Stakes in the Myasthenia Gravis Market

Dianthus Therapeutics, Inc. ($DNTH) announced an update on their ongoing clinical study. Dianthus Therapeutics, Inc. is running a...

3M ago

DNTH

Dianthus initiates EMERGE trial of claseprubart

Dianthus (DNTH) announced initiation of the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis. EMERGE is...

3M ago

DNTH

87E FAQ

What was Dianthus Therapeutics’s price range in the past 12 months?

Dianthus Therapeutics lowest stock price was €28.40 and its highest was €99.50 in the past 12 months.

What is Dianthus Therapeutics’s market cap?

Dianthus Therapeutics’s market cap is €4.39B.

When is Dianthus Therapeutics’s upcoming earnings report date?

Dianthus Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 31 days.

How were Dianthus Therapeutics’s earnings last quarter?

Dianthus Therapeutics released its earnings results on Aug 04, 2026. The company reported -€0.795 earnings per share for the quarter, missing the consensus estimate of -€0.747 by -€0.048.

Is Dianthus Therapeutics overvalued?

According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dianthus Therapeutics pay dividends?

Dianthus Therapeutics does not currently pay dividends.

What is Dianthus Therapeutics’s EPS estimate?

Dianthus Therapeutics’s EPS estimate is -0.83.

How many shares outstanding does Dianthus Therapeutics have?

Dianthus Therapeutics has 55,934,380 shares outstanding.

What happened to Dianthus Therapeutics’s price movement after its last earnings report?

Dianthus Therapeutics reported an EPS of -€0.795 in its last earnings report, missing expectations of -€0.747. Following the earnings report the stock price went up 3.261%.

Which hedge fund is a major shareholder of Dianthus Therapeutics?

Currently, no hedge funds are holding shares in DE:87E

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Dianthus Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

272.08%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics (87E) Earnings & Revenues

Historic Earnings Reports

87E Stock 12 Month Forecast

Average Price Target

€126.84

▲(40.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"€28","103":"€103","178":"€178","65.5":"€65.5","140.5":"€140.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":177.630148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€177.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":126.84407386727275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€126.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.35439028,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€108.35</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,65.5,103,140.5,178],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.5,87.04847292307693,94.59694584615384,102.14541876923077,109.69389169230769,117.24236461538462,124.79083753846155,132.33931046153845,139.88778338461537,147.4362563076923,154.98472923076923,162.53320215384616,170.0816750769231,{"y":177.630148,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.5,83.14185183594405,86.78370367188812,90.42555550783217,94.06740734377624,97.70925917972029,101.35111101566434,104.99296285160841,108.63481468755246,112.27666652349652,115.91851835944058,119.56037019538464,123.20222203132869,{"y":126.84407386727275,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.5,81.71956848307693,83.93913696615385,86.15870544923077,88.37827393230769,90.59784241538462,92.81741089846155,95.03697938153846,97.25654786461538,99.47611634769231,101.69568483076924,103.91525331384616,106.13482179692309,{"y":108.35439028,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.5,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >